Latest News and Press Releases

TAGRISSO™ (OSIMERTINIB) approved in japan for PATIENTS WITH EGFR T790M mutation -positive metastatic non-small cell lung cancer Full approval is based on two Phase II trials, AURA extension and...

Transaction by Persons Discharging Managerial Responsibilities Disclosure Rule DTR 3.1.4 On 24 March 2016, the individuals listed below, who are all persons discharging managerial responsibilities,...

ASTRAZENECA REPORTS TOP-LINE RESULTS FROM THE BRILINTA SOCRATES TRIAL IN STROKE Missed primary efficacy endpoint; fewer events observed in the Brilinta arm but trend did not reach statistical...

NOTICE OF ANNUAL GENERAL MEETING AstraZeneca PLC (the Company) announced today the publication of its Notice of Annual General Meeting 2016 and Shareholders' Circular, together with a covering letter...

FILING OF ANNUAL REPORT ON FORM 20-F WITH THE US SECURITIES AND EXCHANGE COMMISSION AstraZeneca PLC (the Company) announced today that it filed its Annual Report on Form 20-F with the US Securities...

ANNUAL FINANCIAL REPORT AstraZeneca PLC (the Company) announced today the publication of its Annual Report and Form 20-F Information 2015 (Annual Report). A copy of the Annual Report will be...

ASTRAZENECA REPORTS TOP-LINE RESULT OF TREMELIMUMAB MONOTHERAPY TRIAL IN MESOTHELIOMA Trial did not meet primary endpoint of improving overall survival in challenging to treat mesothelioma patients...

ASTRAZENECA ENTERS LICENSING AGREEMENT WITH CHINA MEDICAL SYSTEM HOLDINGS FOR HYPERTENSION MEDICINE Agreement for Plendil in China reinforces AstraZeneca's focus on...

Transaction by Person Discharging Managerial Responsibilities Disclosure Rule DTR 3.1.4 On 25 February 2016, the interest of Mr Pascal Soriot, a person discharging managerial responsibilities, in...

Acalabrutinib RecommendEd for Orphan Drug Designation IN EUROPE for THREE indications AstraZeneca and Acerta Pharma BV, a company in which AstraZeneca has a majority equity investment, today...